Forecast

The analysts' average price target is €29.35 (+252.34%). The median is €28.05 (+236.73%).

Buy	4
Hold	1
Sell	0

News Go to news feed

BioAge Labs stock plunges after Novo Nordisk phase‑3 failure

BioAge Labs shares fell 51.9% in premarket trading after Novo Nordisk’s IL‑6 inhibitor ziltivekimab showed no reduced risk of major cardiovascular events versus placebo in the phase‑3 ZEUS trial. The result calls into question the underlying assumption that blocking upstream inflammatory pathways confers cardiovascular benefit and directly weakens the prospects for BioAge’s oral NLRP3 inhibitor BGE‑102 in the ongoing phase‑2 QUELL‑CV study. Investors have markedly downgraded the likelihood of a positive outcome for BGE‑102 after a well‑funded, thematically related program failed. » More on de.investing.com
HitGen partner BioAge begins phase‑2 trial of NLRP3 inhibitor BGE-102

BioAge has dosed the first participant in a randomized, double-blind, placebo-controlled phase‑2 dose-finding study of the oral NLRP3 inhibitor BGE-102. The QUELL-CV study aims to determine the optimal dose for phase‑3 development in participants with increased cardiovascular risk; topline data are expected in the second half of 2026. BGE-102 was developed from a compound identified using HitGen’s DNA-Encoded-Library (DEL) technology platform; phase‑1 data showed a reduction in high-sensitivity CRP. The partnership between HitGen and BioAge began in 2021 and underscores the application of HitGen’s DEL platform. » More on de.investing.com
Bioage Labs reaches new 52-week high at $25.8

Shares of Bioage Labs rose to a 52-week high of $25.8 and are currently trading around $25.53, giving a market capitalization of about $1.12 billion. Analysts say the stock is near or above fair‑value estimates despite strong price gains (up 486% last year), while the RSI points to overbought conditions. At the same time, BioAge Labs is dosing the first participant in a Phase‑2 trial of BGE‑102 after positive Phase‑1 results showing a reduction in an inflammation marker; Roth/MKM and Jefferies have reaffirmed buy ratings. » More on de.investing.com

Financials

In the last quarter, BIOAGE LABS INC. O.N. Aktie had revenue of €2.15M and net profit of -€22.87M

(EUR)	Jun 2026	YoY
Revenue	2.15M	4.95%
Gross profit	2.15M	4.95%
Net profit	-22.87M	24.99%
EBITDA	-22.8M	26.17%

Fundamentals

Metric	Value
Market capitalization	€313.58M
Number of shares	37.65M
52-week high/low	€22.40 - €3.93
Dividends	No
Beta	0.93
P/E ratio	-4.05
PEG ratio	0.55
P/B ratio	1.15
P/S ratio	35.09

Company profile

BioAge Labs, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das therapeutische Produktkandidaten für Stoffwechselkrankheiten entwickelt. Die Technologieplattform des Unternehmens und die differenzierten menschlichen Datensätze ermöglichen es den Anwendern, Targets auf der Grundlage von Erkenntnissen über molekulare Veränderungen, die das Altern vorantreiben, zu identifizieren. Zu den Produkten des Unternehmens gehört Azelaprag, ein oral verfügbares kleines Molekül, das sich in der klinischen Prüfung der Phase 1 zur Behandlung von Fettleibigkeit befindet; außerdem wurde eine klinische Prüfung der Phase 2 mit Azelaprag in Kombination mit Tirzepatid zur Behandlung von Fettleibigkeit bei älteren Erwachsenen eingeleitet. Das Unternehmen entwickelt außerdem BGE-100, einen oral verfügbaren niedermolekularen NLRP3-Antagonisten zur Behandlung von Krankheiten, die durch Neuroinflammation verursacht werden. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Sitz in Richmond, Kalifornien.